New Imaging Scan Tested for Detecting and Characterizing Endometriosis Lesions
Tests a new PET scan to find endometriosis lesions in adults before surgery.
Plain-language title generated from the registry record
Registry title: Use of a New Diagnostic Tool in the Detection and Characterization of Endometriosis Lesions
Key facts
- Where
- Toulouse Cedex 9, FranceSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Source: NCT07053982, who can take part
Where in France
- Centre Hospitalier Universitaire De ToulouseToulouse Cedex 9, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Toulouse
- Trial code
- NCT07053982EU 2025-520637-24-00
- Record updated
- 25 March 2026
- Original description
Diagnostic wandering is one of the characteristics of endometriosis due to great anatomical and clinical variability but also due to poorly relevant diagnostic examinations. [18F]-FES PET/CT could on the one hand improve diagnosis by showing greater sensitivity than MRI and on the other hand make it possible to quantify and characterize the expression of ER from diagnosis and thus helping to guide therapeutic care. We will thus attempt to correlate the intensity of [18F]-FES PET/CT with the expression of estrogen receptors and the intensity of pain.Read full original descriptionShow less
18F]-FES PET in the Detection and Characterization of Endometriosis Lesions
Diagnostic wandering is one of the characteristics of endometriosis due to great anatomical and clinical variability but also due to poorly relevant diagnostic examinations. [18F]-FES PET/CT could on the one hand improve diagnosis by showing greater sensitivity than MRI and on the other hand make it possible to quantify and characterize the expression of ER from diagnosis and thus helping to guide therapeutic care. We will thus attempt to correlate the intensity of [18F]-FES PET/CT with the expression of estrogen receptors and the intensity of pain.
Inclusion: Cases:; Painful patients with a VAS ≥ 4 treated surgically for painful symptoms related to endometriosis; Controls:; Patient with a VAS < 4 treated surgically for endometriosis in the context of infertility; Age > 18 years; Patient who provided informed consent; Patients who underwent a preoperative MRI and were not contraindicated for [18F]-FES PET/CT; Patient who underwent surgery mid-cycle; Affiliation to a social security scheme.
Exclusion: Patient treated for endometriosis without surgery; Patient taking hormone therapy; Hypersensitivity to the active substance (Fluoroestradiol (18F)) or to any of the excipients; Pregnant patient; Menopausal patient; Patient under legal protection; Claustrophobic patient.